Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (141-150 of 264) with videos related to

Pageof 27
Sort By:
Acta Dermato-Venereologica|January 21, 2021
Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell LymphomaStefanie Porkert, Pamela Mai, Constanze Jonak, et al.
Haematologica|April 2, 2009
A phase II study of bortezomib in patients with MALT lymphomaMarlene Troch, Constanze Jonak, Leonhard Müllauer, et al.
Thyroid : Official Journal of the American Thyroid Association|August 18, 2016
Sustained Response to Vemurafenib in a BRAF<sup>V600E</sup>-Mutated Anaplastic Thyroid Carcinoma PatientGerald W Prager, Oskar Koperek, Marius E Mayerhoefer, et al.
Oncology|December 6, 2003
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancerBirgit Schüll, Gabriela V Kornek, Katharina Schmid, et al.
Endocrine-Related Cancer|June 2, 2026
B7-H3 (CD276) as a Candidate Therapeutic Target in Medullary Thyroid CancerTeresa Binter, Erwin Tomasich, Philipp Melhorn, et al.
Anti-Cancer Drugs|April 18, 2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001Michael Hejna, Markus Raderer, Johannes Zacherl, et al.
Endocrine-Related Cancer|January 12, 2024
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasmsPhilipp Melhorn, Peter Mazal, Ladislaia Wolff, et al.
Molecular Imaging and Biology|March 9, 2019
Pre-Therapeutic Total Lesion Glycolysis on [<sup>18</sup>F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based ImmunotherapyMarius E Mayerhoefer, Anton Staudenherz, Barbara Kiesewetter, et al.
Haematologica|January 29, 2008
Dissemination patterns in non-gastric MALT lymphomaJan Paul de Boer, Reinier Frederik Hiddink, Markus Raderer, et al.
Journal of Dermatological Science|September 23, 2011
High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomasJulia Valencak, Katharina Schmid, Franz Trautinger, et al.
Pageof 27

Showing results (141-150 of 264) with videos related to

Sort By:
Pageof 27
Acta Dermato-Venereologica|January 21, 2021
Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell LymphomaStefanie Porkert, Pamela Mai, Constanze Jonak, et al.
Haematologica|April 2, 2009
A phase II study of bortezomib in patients with MALT lymphomaMarlene Troch, Constanze Jonak, Leonhard Müllauer, et al.
Thyroid : Official Journal of the American Thyroid Association|August 18, 2016
Sustained Response to Vemurafenib in a BRAF<sup>V600E</sup>-Mutated Anaplastic Thyroid Carcinoma PatientGerald W Prager, Oskar Koperek, Marius E Mayerhoefer, et al.
Oncology|December 6, 2003
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancerBirgit Schüll, Gabriela V Kornek, Katharina Schmid, et al.
Endocrine-Related Cancer|June 2, 2026
B7-H3 (CD276) as a Candidate Therapeutic Target in Medullary Thyroid CancerTeresa Binter, Erwin Tomasich, Philipp Melhorn, et al.
Anti-Cancer Drugs|April 18, 2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001Michael Hejna, Markus Raderer, Johannes Zacherl, et al.
Endocrine-Related Cancer|January 12, 2024
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasmsPhilipp Melhorn, Peter Mazal, Ladislaia Wolff, et al.
Molecular Imaging and Biology|March 9, 2019
Pre-Therapeutic Total Lesion Glycolysis on [<sup>18</sup>F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based ImmunotherapyMarius E Mayerhoefer, Anton Staudenherz, Barbara Kiesewetter, et al.
Haematologica|January 29, 2008
Dissemination patterns in non-gastric MALT lymphomaJan Paul de Boer, Reinier Frederik Hiddink, Markus Raderer, et al.
Journal of Dermatological Science|September 23, 2011
High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomasJulia Valencak, Katharina Schmid, Franz Trautinger, et al.
Pageof 27